On March 13, 2026, Lyra Therapeutics, Inc. received a notification from the Nasdaq Hearings Advisor confirming the company's withdrawal of its appeal regarding a delisting determination issued by Nasdaq's Listings Qualifications Staff on February 2, 2026. As a result of this withdrawal, trading of Lyra's common stock will be suspended at the opening of trading on March 17, 2026. The company has indicated that Nasdaq will file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission after all internal procedural periods have concluded. This development is significant as it marks a critical juncture for Lyra Therapeutics, which has faced challenges in maintaining its listing on the Nasdaq exchange. The withdrawal of the appeal suggests that the company may be unable to meet the necessary listing standards, which could have substantial implications for its operations and investor confidence. The suspension of trading is expected to lead to a decrease in liquidity for shareholders and may impact the company's ability to raise capital in the future. Investors should closely monitor further developments regarding Lyra's strategic plans and any potential restructuring efforts that may arise from this situation.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.